<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03197883</url>
  </required_header>
  <id_info>
    <org_study_id>206827</org_study_id>
    <nct_id>NCT03197883</nct_id>
  </id_info>
  <brief_title>Assessment of the Cosmetic Benefit of a Skin Cream in Healthy Females With Mild to Advanced Photo-damaged Facial Skin Who Have Undergone a Glycolic Acid Facial Peel Procedure</brief_title>
  <official_title>A Randomized, Evaluator-blind, Single-center and Two-arm Clinical Study Designed to Evaluate the Local Tolerance and Cosmetic Efficacy of a Topical Skin Care Formulation in Healthy Female Subjects With Mild to Advanced Photo-damaged Facial Skin Who Have Undergone a 70% Glycolic Acid Facial Peel Procedure.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the local tolerance and cosmetic efficacy of a topical skin care formulation in
      healthy female participants with mild to advanced photo-damaged facial skin who have
      undergone a 70% Glycolic Acid facial peel procedure.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This will be a randomized, evaluator-blind, single-center and two-arm clinical study designed
      to evaluate the local tolerance and cosmetic efficacy of a topical skin care formulation in
      healthy female participants with mild to advanced photo-damaged facial skin who have
      undergone a 70% Glycolic Acid facial peel procedure.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 17, 2017</start_date>
  <completion_date type="Actual">October 31, 2017</completion_date>
  <primary_completion_date type="Actual">October 31, 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Dermatologist global assessment of tolerance</measure>
    <time_frame>14 days after completion of the facial peel procedure</time_frame>
    <description>The Dermatologist will assess the local tolerance of the post-procedure skin care regimen in context of the expected effects of the procedure for each participant using the scale below: 0 - Product regimen was well tolerated (No clinically significant worsening of the expected signs/symptoms of the procedure. No new signs/symptoms manifest during product use) and 1 - Product regimen was not well tolerated (Clear, clinically relevant worsening of the severity or frequency of expected signs/symptoms of the procedure and/or any occurrence of new, unexpected signs/symptoms during product use). The Dermatologist will draw on the total set of clinical and participant self-assessment data for each participant.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in sum of Dermatologist scores for signs/symptoms of erythema, edema, desquamation and dryness</measure>
    <time_frame>14 days after completion of the facial peel procedure</time_frame>
    <description>The signs/symptoms of participants will be scored on a scale of 0 to 3. Erythema: Score from 0=None-No evidence of erythema present, 1=Mild-Slight red coloration, 2=Moderate-Definite redness, 3=Severe-Marked erythema, bright red to dusky dark red in color. Dryness: Score from 0=None-No dryness, 1=Mild-Barely perceptible, fine scales or flakes present to limited areas of the test site, 2=Moderate-Fine scales or flakes generalized to all areas of the test site, 3=Severe -Scaling and peeling of skin over all areas of the test site. Desquamation score from 0=None-No evidence of desquamation/peeling, 1=Mild-Barely perceptible scaling; evident only on scratching, 2=Moderate-Minimal scaling, adherent to the skin, 3=Severe -Moderate scaling, loosely adherent to the skin and easily removable. Edema score from 0=None-No edema present, 1=Mild-Barely perceptible edema present, 2=Moderate-Definite edema present, 3=Severe-Marked/pronounced edema present.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Individual Dermatologist scores for erythema, edema, desquamation and dryness</measure>
    <time_frame>14 days after completion of the facial peel procedure</time_frame>
    <description>The signs/symptoms of participants will be scored on a scale of 0 to 3. Erythema: Score from 0=None-No evidence of erythema present, 1=Mild-Slight red coloration, 2=Moderate-Definite redness, 3=Severe-Marked erythema, bright red to dusky dark red in color. Dryness: Score from 0=None-No dryness, 1=Mild-Barely perceptible, fine scales or flakes present to limited areas of the test site, 2=Moderate-Fine scales or flakes generalized to all areas of the test site, 3=Severe -Scaling and peeling of skin over all areas of the test site. Desquamation score from 0=None-No evidence of desquamation/peeling, 1=Mild-Barely perceptible scaling; evident only on scratching, 2=Moderate-Minimal scaling, adherent to the skin, 3=Severe -Moderate scaling, loosely adherent to the skin and easily removable. Edema score from 0=None-No edema present, 1=Mild-Barely perceptible edema present, 2=Moderate-Definite edema present, 3=Severe-Marked/pronounced edema present.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in sum of participant self-assessment scores for redness, pain, stinging/burning, itching, tightness and dryness</measure>
    <time_frame>14 days after completion of the facial peel procedure</time_frame>
    <description>The following assessments will be conducted by participants reflective of their skin condition at the time of evaluation. Participants will score following signs/symptom: pain, stinging/burning, itching, tightness, redness and dryness on scale of 0 to 3. (0= None, 1= Mild, 2= Moderate, and 3= Severe).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in participant self-assessment scores for redness</measure>
    <time_frame>14 days after completion of the facial peel procedure</time_frame>
    <description>The following assessments will be conducted by participants reflective of their skin condition at the time of evaluation for redness. Participants will score on a scale of 0 to 3. (0= None, 1= Mild, 2= Moderate, and 3= Severe).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in participant self-assessment scores for pain</measure>
    <time_frame>14 days after completion of the facial peel procedure</time_frame>
    <description>The following assessments will be conducted by participants reflective of their skin condition at the time of evaluation for pain. Participants will score on a scale of 0 to 3. (0= None, 1= Mild, 2= Moderate, and 3= Severe).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in participant self-assessment scores for itching</measure>
    <time_frame>14 days after completion of the facial peel procedure</time_frame>
    <description>The following assessments will be conducted by participants reflective of their skin condition at the time of evaluation for itching. Participants will score on a scale of 0 to 3. (0= None, 1= Mild, 2= Moderate, and 3= Severe).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in participant self-assessment scores for stinging/burning</measure>
    <time_frame>14 days after completion of the facial peel procedure</time_frame>
    <description>The following assessments will be conducted by participants reflective of their skin condition at the time of evaluation for stinging/burning. Participants will score on a scale of 0 to 3. (0= None, 1= Mild, 2= Moderate, and 3= Severe).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in participant self-assessment scores for tightness</measure>
    <time_frame>14 days after completion of the facial peel procedure</time_frame>
    <description>The following assessments will be conducted by participants reflective of their skin condition at the time of evaluation for tightness. Participants will score on a scale of 0 to 3. (0= None, 1= Mild, 2= Moderate, and 3= Severe).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in participant self-assessment scores for dryness</measure>
    <time_frame>14 days after completion of the facial peel procedure</time_frame>
    <description>The following assessments will be conducted by participants reflective of their skin condition at the time of evaluation for dryness. Participants will score on a scale of 0 to 3. (0= None, 1= Mild, 2= Moderate, and 3= Severe).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in instrumental measurement of barrier function using Tewameter</measure>
    <time_frame>14 days after completion of the facial peel procedure</time_frame>
    <description>Trans-epidermal water loss (TEWL) measurement will be performed by evaporimetry with a Tewameter. Measurements will be taken in triplicate on the left cheek (below the cheekbone between the nose and ear). TEWL measurements will be taken with the participant lying horizontally, on their back, so that the chimney of the Tewameter probe is aligned vertically.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in instrumental measurement of moisturisation using Corneometer</measure>
    <time_frame>14 days after completion of the facial peel procedure</time_frame>
    <description>Measurement of stratum corneum hydration will be performed by the electrical capacitance method with a Corneometer. Corneometer measurements will be taken in triplicate at the left cheek (below the cheekbone, between the nose and ear) with the participant lying horizontally, on their back.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Participant's global self-assessment</measure>
    <time_frame>14 days after completion of the facial peel procedure</time_frame>
    <description>Participants will rate the level of satisfaction with the post-procedure skin care regimen to which they were randomized using scale as follows: 0 (Very satisfied), 1 (Satisfied), 2 (Poorly satisfied), 3 (Not at all satisfied).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">122</enrollment>
  <condition>Skin Care</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will apply a pea-sized quantity of test product (approximately 0.6-1 grams (g)) topically onto the fingertips and will apply twice daily (morning and evening) to the full face after cleansing. All participants will be instructed to continue using the facial cleanser twice-daily during the morning and evening and to apply the sunscreen in the morning (after application of test product) and at lunchtime.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Participants will wet face with water and work a small amount of facial cleanser (approximately 0.6-1 g) into lather. Massage topically onto wet skin and rinse with water twice daily (morning and evening). After cleansing, participants will apply a pea-sized quantity (approximately 0.6-1 g) of the sunscreen in the morning and at lunchtime.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Test Product</intervention_name>
    <description>Restoring lipid balm</description>
    <arm_group_label>Group 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Cleanser</intervention_name>
    <description>Moisturizing facial cleanser</description>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_label>Group 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Sunscreen</intervention_name>
    <description>SPF (Sun Protection Factor) 50 sunscreen</description>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_label>Group 1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Demonstrates understanding of the study procedures, restrictions and willingness to
             participate as evidenced by voluntary written informed consent and has received a
             signed and dated copy of the informed consent form.

          -  Females aged between 30 and 60 years inclusive.

          -  Good general and mental health with, in the opinion of the investigator or medically
             qualified designee no clinically significant and relevant abnormalities in medical
             history or upon physical examination.

          -  Willingness to actively participate in the study and to attend all scheduled visits.

          -  Skin Type: Fitzpatrick phototype II-IV and participants with Glogau photoaging type
             II-III

          -  Females of childbearing potential who are, in the opinion of the investigator,
             practising a reliable method of contraception. Adequate contraception is defined as
             abstinence, oral contraceptive, either combined or progestogen alone or injectable
             progestogen or implants of levonorgestrel or estrogenic vaginal ring or percutaneous
             contraceptive patches or intrauterine device or intrauterine system or double barrier
             method (condom or occlusive cap [diaphragm or cervical vault caps] plus spermicidal
             agent [foam, gel, film, cream, suppository]) or male partner sterilization prior to
             the female participant's entry into the study, and this male is the sole partner for
             that participant.

        Exclusion Criteria:

          -  Women who are known to be pregnant or who are intending to become pregnant over the
             duration of the study.

          -  Women who are breast-feeding.

          -  a) Active skin disease or open wound in the test area, b) Medical history of using a
             medicated acne treatment (e.g. Benzoyl Peroxide, Clindamycin, isotretinoin) within the
             last 24 months, c)Medical history of dysplastic nevi or melanoma, d) Preexisting
             inflammatory dermatoses such as psoriasis, atopic dermatitis, e) Moles, tattoos,
             scars, irritated skin, hairs, etc. at the test area that could, in the opinion of the
             investigator, influence the investigation, f) Systemic therapy with immuno-suppressive
             drugs (e.g. corticosteroids) and/or antihistamines within 7 days prior to screening
             and/or throughout the entire course of the study, g) Systemic use of over-the-counter
             (OTC) analgesics or anti-inflammatory drugs 24 hours prior to screening. h)Systemic
             use of any photosensitizing medication 2 weeks prior to screening, i) Intense sun
             exposure, UV-treatments or tanning salon visit within two weeks prior to screening, j)
             One of the following illnesses that might require regular systemic medication;
             Insulin-dependent diabetes, cancer, k) One of the following illnesses if not
             medicated: Asthma, hypertension, l) Medical history of abnormal response to sunlight,
             m) Participant's with a history of mental illness, n) Ocular surgery within the last
             12 months.

             o) Ocular trauma, infection or inflammation within the last 3 months, p) Active
             blepharitis, conjunctivitis, uveitis, q) Any ocular pathology requiring topical ocular
             treatment within the last 1 month, r) Ocular laser within the last 3 months, s)
             Aesthetic, cosmetic or dermatological treatment in the treatment area (face),
             including the use of skin tone lightning products, within the last 3 months, t) Use of
             facial scrubs, depilatory creams, waxing and/or bleaching within the last 2 weeks
             prior to screening, u) Microdermabrasion and/or laser hair removal within the last 4
             weeks prior to screening, v) Medical history of Herpes Simplex (Cold Sores).

          -  Known or suspected intolerance or hypersensitivity to the study materials (or closely
             related compounds) or any of their stated ingredients and documented allergies to
             cosmetic products or study ingredients.

          -  Participation in another clinical study (including cosmetic studies) or receipt of an
             investigational drug within 30 days of the screening visit and previous participation
             in this study.

          -  Recent history (within the last 5 years) of alcohol or other substance abuse.

          -  An employee of the sponsor or the study site or members of their immediate family.

          -  Required to work outside during daylight hours over the duration of the study and
             required or otherwise intending to spend prolonged periods of time outside during
             daylight hours over the duration of the study (e.g. holiday, sunbathing, and
             gardening).

          -  A score of &quot;Severe&quot; for any Dermatologist or Participant's Self-Assessed endpoint at
             any time for the study material sensitivity test.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Campinas</city>
        <state>SÃ£o Paulo</state>
        <zip>13084-791</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 8, 2017</study_first_submitted>
  <study_first_submitted_qc>June 21, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 23, 2017</study_first_posted>
  <last_update_submitted>April 5, 2018</last_update_submitted>
  <last_update_submitted_qc>April 5, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 6, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sunscreening Agents</mesh_term>
    <mesh_term>Glycolic acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

